Stockholm, September 28, 2022 – Umecrine Cognition AB today announced results showing that the company’s clinical drug candidate golexanolone largely eliminated fatigue in a preclinical disease…
STOCKHOLM – September 14, 2022. Umecrine Cognition today announces that the company has secured funding of SEK 41 million for the start of a Phase 2 study of its drug candidate golexanolone in…
SOLNA – August 10, 2022. Umecrine Cognition AB today announces that its Board of Directors has appointed Anders Karlsson as new CEO. He succeeds Magnus Doverskog, who will move on to a position as…
The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the extraordinary general meeting at 10:00 a.m. on Wednesday 10 August 2022. The meeting will be…
STOCKHOLM – May 19, 2022. Umecrine Cognition AB today announces that the company has submitted a clinical trial application (CTA) for a Phase 2 study of golexanolone in patients with primary…
The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 10:00 a.m. on Friday 17 June 2022 at Setterwalls Advokatbyrå’s…
STOCKHOLM – March 14, 2022. Umecrine Cognition AB today announces that the company has completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA). Based on a recent interaction…
STOCKHOLM – February 21, 2022. Umecrine Cognition AB today announces that the company will present positive data from a recently concluded nonclinical study at the 11th International Meeting on…
Stockholm, January 10, 2022 – Umecrine Cognition AB today announced nonclinical results showing that its clinical drug candidate golexanolone exerts a normalizing effect on neuroinflammation in the…
STOCKHOLM – Umecrine Cognition AB today announces new scientific results for its drug candidate golexanolone, linking the drug target allopregnanolone to cognitive symptoms in patients with primary biliary cholangitis. The data will be presented at The Liver Meeting Digital ExperienceTM 2021, the premier Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 12-15.